ACR 2022 Tweet by Robert B Chao, MD

Good news for patients who require short interruptions in biologic therapy!
Majority of axSpA patients (82%) who restarted ixekizumab after withdrawing, achieved low disease activity and 68% eventually had inactive disease.
#Abs0427 @RheumNow #ACR22